<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639779</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-18-14095</org_study_id>
    <nct_id>NCT03639779</nct_id>
  </id_info>
  <brief_title>A Comparative Study of the Efficacy of Intralesional Sodium Thiosulfate Versus Intralesional Normal Saline for the Treatment of Dystrophic and Idiopathic Calcinosis Cutis</brief_title>
  <official_title>A Comparative Study of the Efficacy of Intralesional Sodium Thiosulfate Versus Intralesional Normal Saline for the Treatment of Dystrophic and Idiopathic Calcinosis Cutis, A Double-Blind Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Central Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Central Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of our research is to compare the effectiveness of 125mg/50ml sodium thiosulfate
      (STS) solution to normal saline (0.9% sodium chloride) when injected intralesionally for the
      treatment of calcinosis cutis. Our specific aim is to assess the response of dystrophic and
      idiopathic calcinosis cutis to the injections of sodium thiosulfate in our patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our specific aim is to assess the response of dystrophic and idiopathic calcinosis cutis to
      the injections of sodium thiosulfate in our patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Time and resource constraints
  </why_stopped>
  <start_date type="Actual">November 2, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a parallel two-arm study comparing sodium thiosulfate and saline control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion Size</measure>
    <time_frame>3 months</time_frame>
    <description>The lesion size is measured in centimeters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physician Global Assessment (PGA)</measure>
    <time_frame>3 months</time_frame>
    <description>The PGA will be done by the physician to assess appearance and changes in the lesion. The lesion will be assigned a score from 0 (clear) to 4 (severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) for Pain</measure>
    <time_frame>3 months</time_frame>
    <description>The VAS for pain is used to assess the pain associated with the lesion. The pain will be recorded as a number from 1 (no pain) to 10 (severe pain).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Calcinosis Cutis</condition>
  <arm_group>
    <arm_group_label>Sodium thiosulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 ml vials of sodium thiosulfate (250mg/ml) will be used for treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 ml vials of sodium chloride 0.9% will be used for the control treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Thiosulfate</intervention_name>
    <description>A volume of 0.1 ml/cm2 of STS will be injected into each lesion.</description>
    <arm_group_label>Sodium thiosulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>A volume of 0.1 ml/cm2 of normal saline will be injected into the control lesion.</description>
    <arm_group_label>Saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adult 18 years of age or older

          -  Must have health insurance will be eligible to participate

          -  Must have a current diagnosis of dystrophic or idiopathic calcinosis cutis

          -  Subjects must have at least 2 lesions of at least 2mm in size

        Exclusion Criteria:

          -  Unable to read and speak English

          -  Allergy to any component of the sodium thiosulfate solution

          -  Adults unable to consent

          -  Individuals who are not yet adults (infants, children, teenagers)

          -  Pregnant women

          -  Women who are breastfeeding

          -  Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCF Health Lake Nona Office</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32832</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Central Florida</investigator_affiliation>
    <investigator_full_name>David Weinstein</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Calcinosis cutis</keyword>
  <keyword>sodium thiosulfate</keyword>
  <keyword>sodium chloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium thiosulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

